Quick answer
What is hexarelin, in one paragraph? Hexarelin is a synthetic hexapeptide, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 (C47H58N12O6, about 887 g/mol calculated), derived from the GHRP-6 scaffold and studied as an agonist of the growth hormone secretagogue receptor GHS-R1a. It was described in the early 1990s, the receptor was cloned in 1996 and ghrelin was identified as the natural ligand in 1999. The V8 vial is a 5 mg lyophilized powder at ≥98% HPLC purity. This page is a profile; for assay design start from the research overview. For laboratory research use only; not for human consumption.
Reference profiles are useful when a project starts with a simple question: what exactly is this molecule, where did it come from and what has been published about it? This page answers those questions for hexarelin in a fixed order: identity, structure, naming, timeline, analytical facts and open questions. It contains no assay protocol and no claim about effects beyond what the cited papers reported. The material is supplied for laboratory research use only.
Identity card
The values below come from the live hexarelin product page, apart from the calculated molecular weight, which is derived from the stated formula.
| Attribute | Value |
|---|---|
| Compound | Hexarelin (examorelin) |
| Class | Synthetic hexapeptide, GH secretagogue |
| Sequence | His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Molecular formula | C47H58N12O6 |
| Calculated average mass | About 887 g/mol (sum of standard atomic weights) |
| Vial size | 5 mg |
| Purity | ≥98% by HPLC |
| Supplied form | Lyophilized powder, sealed clear glass vial |
| Storage | 2–8 °C; −20 °C for long-term; protect from heat, moisture and light |
| Documentation | Batch-specific COA, where published, in the COA library |
HPLC purity describes the fraction of the chromatographic signal that belongs to the main peak. It does not report net peptide content, which is lower because counterions and residual water occupy part of the vial mass. The distinction is explained in understanding HPLC purity. Moles in a vial are mass divided by molar mass (n = m / M), and the working concentration after dissolving is c = n / V, so the same two quantities appear again and again in the arithmetic; the calculator handles the unit conversions.
Structure: how hexarelin differs from GHRP-6
Hexarelin belongs to the family of synthetic GH-releasing peptides that began with GHRP-6. GHRP-6 has the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Set that beside hexarelin and a single change is visible: the D-tryptophan at position 2 carries a methyl group on the indole ring. Everything else, including the free N-terminal histidine and the C-terminal amide, is retained.
| Position | GHRP-6 | Hexarelin | Chemical note |
|---|---|---|---|
| 1 | His | His | Free N-terminus |
| 2 | D-Trp | D-2-methyl-Trp | Methyl group on the indole ring; D configuration |
| 3 | Ala | Ala | Small, neutral spacer |
| 4 | Trp | Trp | L configuration; aromatic and light-sensitive |
| 5 | D-Phe | D-Phe | D configuration; aromatic |
| 6 | Lys-NH2 | Lys-NH2 | C-terminal amide; basic side chain |
Two chemical consequences are worth noting. The alternation of D and L residues makes the backbone less accessible to proteases, and the extra methyl group adds hydrophobicity to a residue that is already hydrophobic. Neither feature has been shown to determine receptor selectivity on its own, and this profile does not claim it. Side-by-side behavior of related molecules is covered in hexarelin vs GHRP-6.
Names you will meet in the literature
- Hexarelin: the common name and the one used on the product page.
- Examorelin: the international nonproprietary style name for the same molecule.
- Growth hormone-releasing peptide (GHRP): a family term; a paper that says "GHRP" may be about GHRP-6, GHRP-2 or hexarelin, so always check the compound named in the methods.
- GH secretagogue (GHS): a functional term for any ligand of GHS-R1a, including the natural ghrelin.
- GHS-R1a: the receptor, also called the ghrelin receptor.
Dated timeline of key studies
The table lists papers that matter for orientation, each with one line on what it established. Nothing here is a recommendation; the entries are a reading list.
| Year | Study | What it contributed |
|---|---|---|
| 1994 | Ghigo and colleagues, J Clin Endocrinol Metab | Early report describing the GH-releasing activity of hexarelin as a new synthetic hexapeptide, with exposure routes compared |
| 1995 | Roumi and colleagues, Peptides | A radioimmunoassay for hexarelin, the analytical groundwork for later disposition studies |
| 1996 | Howard and colleagues, Science | Cloning of the GH secretagogue receptor from pituitary and hypothalamus |
| 1997 | Ghigo and colleagues, J Clin Endocrinol Metab | Report that hexarelin also affects ACTH and cortisol readouts, relevant to receptor selectivity |
| 1999 | Kojima and colleagues, Nature | Identification of ghrelin as the endogenous ligand of the receptor |
| 1999 | Locatelli and colleagues, Endocrinology | GH-independent cardioprotective effects of hexarelin in the rat |
| 2000 | Roumi and colleagues, Drug Metab Dispos | Kinetics and disposition of hexarelin in rats |
| 2002 | Bodart and colleagues, Circ Res | CD36 proposed as a mediator of cardiac actions of GH-releasing peptides |
| 2004 | Demers and colleagues, Biochem J | Photoaffinity mapping of the peptide binding site on CD36 |
How to read the early hexarelin literature
Several of the earliest papers are physiology studies in people or animals, in which a GH response was the measured endpoint. A laboratory reader should keep three cautions in mind. First, the dose, route and species of each study differ and cannot be transferred to a cell assay; the profile deliberately gives none. Second, the studies predate the cloning of the receptor, so some mechanistic language reflects what was known then. Third, many of the original reports are small and descriptive, which is normal for exploratory work but means replication matters before a finding is built upon.
The 1997 report on ACTH and cortisol is a useful example of why selectivity should be tested rather than assumed. A secretagogue that is described as a GH-releasing peptide may produce other hormonal readouts in intact systems, and any experiment that uses hexarelin as a selective tool should consider including those readouts or at least acknowledging them in the limitations. Desensitization has also been discussed in the literature (Rahim and Shalet, 1998), which is another reason to plan repeated-exposure arms with care.
Analytical identity and what a COA can confirm
With the formula and sequence in hand, an investigator can check what a certificate should show. The expected molecular ion corresponds to the formula above. A COA for a peptide of this size normally reports an HPLC trace with the main peak area and an identity result; where a certificate has been published, it is listed in the COA library. The reasoning behind purity and identity checks for this compound is covered in hexarelin purity testing. If a certificate is not published for a lot in hand, record that in the notebook instead of assuming one exists.
Practical handling points that follow from the profile
The identity card translates into a few bench habits. The two tryptophan residues absorb ultraviolet and room light, so the vial stays in its box and the stock goes into amber or foil-wrapped tubes. The free N-terminal histidine and the lysine side chain carry positive charge at neutral pH, which favors adsorption to negatively charged glass surfaces at low concentration; low-binding plastics and prompt use of dilute working solutions reduce that loss. The C-terminal amide and the D-residues mean that ordinary serum proteases are less of a threat than they are for natural peptides, but oxidation and adsorption remain. Reconstitute by letting the vial warm, adding diluent against the wall and swirling, as set out in how to reconstitute a lyophilized peptide. Record lot, diluent, concentration and date on every tube, and keep the concentration arithmetic as c = m / V rather than copying numbers from a table that assumed a different diluent volume.
What remains unestablished
- No validated shelf life for reconstituted hexarelin has been published; storage practice is therefore based on general peptide handling.
- The relative contribution of GHS-R1a and CD36 to responses in non-pituitary tissues has been examined in only a few models.
- Modern head-to-head receptor pharmacology across the GHRP family, using the same cell system and current assay technology, is sparse.
- Impurity profiles specific to hexarelin synthesis are not described in the primary literature, so identity relies on the certificate and the investigator's own checks.
Introductions at different depths are at what is hexarelin and the hexarelin research overview. The material itself is listed in the research catalog for laboratory research use only.
Related reading
- Hexarelin research overview
- What is hexarelin?
- Hexarelin vs GHRP-6
- Hexarelin purity testing
- Where to buy hexarelin for research
Frequently asked questions
What is the sequence of hexarelin?
His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, a hexapeptide with a C-terminal amide. The formula on the product page is C47H58N12O6.
How does hexarelin differ from GHRP-6?
The D-tryptophan at position 2 carries a methyl group on its indole ring in hexarelin. The remaining five residues are the same as in GHRP-6.
Is hexarelin the same as examorelin?
Yes. Examorelin is the nonproprietary-style name for the same molecule, and some papers use it instead of hexarelin.
What receptor is hexarelin studied at?
The growth hormone secretagogue receptor GHS-R1a, also called the ghrelin receptor. Separate studies have examined CD36 as another binding partner.
When was the ghrelin receptor identified?
The receptor was cloned in 1996 by Howard and colleagues, and ghrelin was identified as its natural ligand in 1999 by Kojima and colleagues.
What is the molecular weight of hexarelin?
About 887 g/mol, calculated from C47H58N12O6 using standard atomic weights. A certificate of analysis reports the measured identity for a given lot.
Does 98% purity mean 98% peptide by weight?
No. HPLC purity is a chromatographic area percentage. Net peptide content is lower because counterions and residual water also contribute to the vial mass.
What size is the hexarelin vial?
The product page lists a single 5 mg vial of lyophilized powder, stored at 2–8 °C with −20 °C for long-term holding.
Has a shelf life for reconstituted hexarelin been published?
Not in the sources reviewed for this profile. General practice is to keep solutions cold, limit time in solution and freeze single-use portions.
Where can the COA for a lot be found?
Certificates are listed in the COA library where they have been published. Match the lot number on the vial to the entry and record the result.
Related reading: Hexarelin Side Effects in Research: What Studies Report, Hexarelin and the Ghrelin Receptor GHS-R1a Explained, How Hexarelin Is Made: Solid-Phase Synthesis Basics.
References
- Ghigo E, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab. 1994;78(3):693-698. doi:10.1210/jc.78.3.693
- Roumi M, Lenaerts V, Boutignon F, et al. Radioimmunoassay for hexarelin, a peptidic growth hormone secretagogue, and its pharmacokinetic studies. Peptides. 1995;16(7):1301-1306. doi:10.1016/0196-9781(95)02022-o
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
- Ghigo E, et al. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab. 1997;82(8):2439-2444. doi:10.1210/jc.82.8.2439
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. doi:10.1038/45230
- Locatelli V, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-4031. doi:10.1210/en.140.9.4024
- Roumi M, Marleau S, du Souich P, et al. Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats. Drug Metab Dispos. 2000;28(1):44-50. doi:10.1016/s0090-9556(24)11760-6
- Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849. doi:10.1161/01.res.0000016164.02525.b4
- Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8(Suppl B):141-143. doi:10.1016/s1096-6374(98)80039-7
